酮洛芬/奥美拉唑(Ketoprofen/Omeprazole) - 药物靶点：PPAR x Proton pump_在研适应症：炎症，疼痛，强直性脊柱炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Omeprazole/ketoprofen、Axorid、Keithon

+ [1]

靶点

PPAR x Proton pump

作用机制

PPAR拮抗剂(过氧化物酶体增殖物活化受体拮抗剂)、质子泵抑制剂

治疗领域

免疫系统疾病感染神经系统疾病+ [2]

在研适应症

炎症疼痛强直性脊柱炎+ [2]

非在研适应症-

原研机构

Meda AB

在研机构

Ethypharm SAS

Meda AB

非在研机构-

最高研发阶段批准上市

首次获批日期

英国 (2008-12-01),

强直性脊柱炎骨关节炎类风湿关节炎

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C17H19N3O3S

InChIKeySUBDBMMJDZJVOS-UHFFFAOYSA-N

CAS号73590-58-6

查看全部结构式(2)

关联

1

项与酮洛芬/奥美拉唑相关的临床试验

NCT00971581 / Completed临床3期

Safety, Tolerability and Efficacy of FDC Ketoprofen + Omeprazole in Patients With Rheumatological Conditions With History or Who Are at Risk of Developing NSAID Associated Benign Gastric Ulcers, Duodenal Ulcers and Gastroduodenal Erosions

Primary Objective:
To confirm the safety and tolerability of the fixed dose combination of a Non-Steroidal Anti-Inflammatory Drug (NSAID), ketoprofen, associated to a Proton Pump Inhibitor (PPI), omeprazole, in Mexican patients.
Secondary Objective:
To confirm the efficacy of the combination:
Relief of pain (Visual Analyzed Score (VAS))
Patients global assessment of disease activity, scored as a scale of 1 (no limitation of normal activities) to 5 (inability to carried out all normal activities)

开始日期2009-08-01

申办/合作机构

Sanofi

100 项与酮洛芬/奥美拉唑相关的临床结果

登录后查看更多信息

100 项与酮洛芬/奥美拉唑相关的转化医学

登录后查看更多信息

100 项与酮洛芬/奥美拉唑相关的专利（医药）

登录后查看更多信息

4

项与酮洛芬/奥美拉唑相关的文献（医药）

1962-09-01·Toxicology and Applied Pharmacology3区 · 医学

The acute and chronic toxicities of chlorphenoxamine

3区 · 医学

Article

作者: James W. Newberne ; David C. Brinkman ; Lawrence C. Weaver ; T.Lamar Kerley

The 50% oral convulsive dose (C.D.₅₀) of chlorphenoxamine (β-dimethylaminoethyl p-chloro-α-methylbenzhydryl ether hydrochloride) (I) in mice was 315 mg./kg., and the L.D.₅₀ value was 575 mg./kg.Comparable values for Keithon (the β-diethyl analog of I) were 470 and 650 mg./kg., resp.The intravenous L.D.₅₀ value of I in dogs was 30.8 mg./kg.Incorporation of 0.166, 0.249, or 0.374% of I in the diet of rats for 26 weeks was without effects attributable to I.When I was fed to dogs daily at 10 mg./kg. for 18 weeks, then for an addnl. 29 weeks at 30 mg./kg. a loss of body weight was noted, and initially an occasional emetic response was seen.No other effects of the drug were noted.

1959-04-11·Die Medizinische

Erfahrungen mit einem neuen Parkinsonmittel Keithon.

Article

作者: FINKE, H

1957-12-01·Medizinische Monatsschrift

[Keithon for therapy of parkinsonism].

Article

100 项与酮洛芬/奥美拉唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	A02BC01	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
炎症	英国	Ethypharm SAS	2009-12-19
疼痛	英国	Ethypharm SAS	2009-12-11
强直性脊柱炎	英国	Meda AB	2008-12-01
骨关节炎	英国	Meda AB	2008-12-01
类风湿关节炎	英国	Meda AB	2008-12-01